Targeted Therapy for Early and Locally Advanced Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer treatment relies on chemotherapy, endocrine therapy, and molecular targeted therapies.
• Understanding breast cancer cell biology drives the development of new targeted therapies.
• Targeted therapies are approved for metastatic breast cancer, but options for early-stage disease are limited.

Purpose of the Study:

• To review the current landscape of molecular targeted therapies for early and locally advanced breast cancer.
• To discuss approved and investigational targeted agents in breast cancer treatment.

Main Methods:

• Review of current literature and clinical trial data.
• Focus on approved and advanced clinical development targeted therapies for breast cancer.

Main Results:

• Trastuzumab is the only approved targeted therapy for early HER2-positive breast cancer (adjuvant/neoadjuvant).
• Lapatinib and bevacizumab, approved for metastatic breast cancer, are under investigation for early-stage disease.
• Several targeted drugs are approved for metastatic breast cancer, targeting diverse molecular pathways.

Conclusions:

• The role of molecular targeted therapies in early and locally advanced breast cancer is expanding.
• Ongoing clinical trials are evaluating the efficacy of targeted agents in earlier stages of breast cancer.
• Personalized medicine approaches utilizing targeted therapies are crucial for improving breast cancer outcomes.